Omicron has shown immune escape from neutralizing antibodies generated through previous infection or vaccination. It could evade the protection provided by mAbs being used in clinics for treating coronavirus disease 2019 (COVID‐19) patients. Booster dose is recommended to elevate the protective levels of antibodies in COVID‐19 vaccinated individuals. The development of powerful oral antiviral drugs such as Molnupiravir and Paxlovid have shown promising clinical results and raised new hopes of COVID‐19 treatment. High efforts are being made to develop highly efficacious vaccines, and by implementing appropriate prevention and control strategies to counter Omicron.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015506 | PMC |
| http://dx.doi.org/10.1002/jmv.27633 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Establishing quality assurance for COVID-19 antigen tests in the Indo Pacific Region: A multi-site implementation study.
Diagn Microbiol Infect Dis
December 2024
Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia.
Background: Quality assurance programs (QAPs) are used to evaluate the analytical quality of a diagnostic test and provide feedback to improve quality processes in testing. Rapid diagnostic tests were used in both laboratory and non-laboratory settings to diagnose COVID-19, although varied in reported performance. We aimed to design and implement a QAP for antigen rapid diagnostic tests (Ag-RDTs) for COVID-19 in Cambodia, Lao PDR, and Papua New Guinea.
View Article and Find Full Text PDFDefining the Critical Requisites for Accurate Simulation of SARS-CoV-2 Viral Dynamics: Patient Characteristics and Data Collection Protocol.
J Med Virol
January 2025
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
Mathematical models of viral dynamics are crucial in understanding infection trajectories. However, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load data often includes limited sparse observations with significant heterogeneity. This study aims to: (1) understand the impact of patient characteristics in shaping the temporal viral load trajectory and (2) establish a data collection protocol (DCP) to reliably reconstruct individual viral load trajectories.
View Article and Find Full Text PDFEstimating cumulative infection rate of COVID-19 after adjusting the dynamic zero-COVID policy in China.
Infect Dis Model
June 2025
School of Public Health, Nanjing Medical University, Nanjing, 211166, China.
Background: At the end of 2022, China adjusted its coronavirus disease 2019 (COVID-19) prevention and control strategy. How this adjustment affected the cumulative infection rate is debated, and how second booster dose vaccination affected the pandemic remains unclear.
Methods: We collected COVID-19 case data for China's mainland from December 7, 2022, to January 7, 2023, reported by the World Health Organization.
Insights into Omicron: Genomic Characterization and Inpatient Risk Assessment at Single Tertiary Hospital in Indonesia.
J Multidiscip Healthc
January 2025
Department of Clinical Pathology, Faculty of Medicine Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung, West Java, Indonesia.
Purpose: Omicron is a variant with the highest number of mutations among all Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) viruses, making whole genome sequencing (WGS) an essential tool for public health surveillance and molecular epidemiology. It is important to note that surveillance data can provide insights into the virus evolution and disease control. This study aims to provide an overview of WGS results for the SARS-CoV-2 Omicron Variant at Hasan Sadikin General Hospital Bandung.
View Article and Find Full Text PDFDevelopment of a Recombinant Omicron BA.1 Subunit Vaccine Candidate in Pichia pastoris.
Microb Biotechnol
January 2025
Izmir Biomedicine and Genome Center, Izmir, Turkey.
Low-cost and safe vaccines are needed to fill the vaccine inequity gap for future pandemics. Pichia pastoris is an ideal expression system for recombinant protein production due to its cost-effective and easy-to-scale-up process. Here, we developed a next-generation SARS-CoV2 Omicron BA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!